Literature DB >> 20490930

Clinical aspects of neuropathic lysosomal storage disorders.

Laura Bannach Jardim1, Maria Mercedes Villanueva, Carolina F Moura de Souza, Cristina B Oliveira Netto.   

Abstract

The purpose of this review is to describe neurological phenotypes associated with lysosomal storage diseases (LSDs), focusing on features arising from primary neuronal involvement. Clinical presentation, progression and genetic data, are discussed in detail in Part 2, the electronic material. Main features are summarized in Part 1. Insights gained from several observational studies are discussed. Prospective studies of the natural history of most neuronopathic LSDs have been hampered by the rarity of these conditions and the short survival of affected patients. Increasingly, longitudinal observations relating to neurological manifestations are being reported. Better clinical studies are necessary, including repeated measurements of disease progression to facilitate the development of sensitive scoring systems and appropriate counseling of affected individuals and their families. Ideally, clinical studies should involve a large cohort. As treatment becomes available, knowledge of disease expression and factors that influence the phenotype may enable critical assessment of therapeutic outcomes. It is hoped that increased familiarity with the clinical expression of individual LSDs will allow early diagnosis, so families at risk are given options to consider during future pregnancies. Early diagnosis also permits the introduction of timely intervention, to favoring improved outcome in cases that are potentially treatable.

Entities:  

Mesh:

Year:  2010        PMID: 20490930     DOI: 10.1007/s10545-010-9079-5

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  62 in total

1.  Neurological deterioration in late infantile neuronal ceroid lipofuscinosis.

Authors:  S Worgall; M V Kekatpure; L Heier; D Ballon; J P Dyke; D Shungu; X Mao; B Kosofsky; M G Kaplitt; M M Souweidane; D Sondhi; N R Hackett; C Hollmann; R G Crystal
Journal:  Neurology       Date:  2007-08-07       Impact factor: 9.910

2.  Sustained neurological improvement following reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation for late-onset Krabbe disease.

Authors:  Z Y Lim; A Y L Ho; S Abrahams; A Fensom; M Aldouri; A Pagliuca; C Shaw; G J Mufti
Journal:  Bone Marrow Transplant       Date:  2008-02-04       Impact factor: 5.483

3.  Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations.

Authors:  Robert Steinfeld; Peter Heim; Henning von Gregory; Kerstin Meyer; Kurt Ullrich; Hans H Goebel; Alfried Kohlschütter
Journal:  Am J Med Genet       Date:  2002-11-01

4.  Marked clinical difference between two sibs affected with juvenile metachromatic leukodystrophy.

Authors:  J T Clarke; M A Skomorowski; P L Chang
Journal:  Am J Med Genet       Date:  1989-05

Review 5.  Laronidase treatment of mucopolysaccharidosis I.

Authors:  Ed J Wraith; John J Hopwood; Maria Fuller; Peter J Meikle; Doug A Brooks
Journal:  BioDrugs       Date:  2005       Impact factor: 5.807

6.  Motor and psycho-cognitive clinical types in adult metachromatic leukodystrophy: genotype/phenotype relationships?

Authors:  Nicole Baumann; Jean-Claude Turpin; Mireille Lefevre; Benoit Colsch
Journal:  J Physiol Paris       Date:  2002 Apr-Jun

7.  Difficulty in recognizing multiple sulfatase deficiency in an infant.

Authors:  Roberto P Santos; Joe J Hoo
Journal:  Pediatrics       Date:  2006-03       Impact factor: 7.124

8.  The neurogenetics of mucolipidosis type IV.

Authors:  G Altarescu; M Sun; D F Moore; J A Smith; E A Wiggs; B I Solomon; N J Patronas; K P Frei; S Gupta; C R Kaneski; O W Quarrell; S A Slaugenhaupt; E Goldin; R Schiffmann
Journal:  Neurology       Date:  2002-08-13       Impact factor: 9.910

9.  Umbilical cord blood transplantation for juvenile metachromatic leukodystrophy.

Authors:  Tyler Mark Pierson; Carsten G Bonnemann; Richard S Finkel; Nancy Bunin; Gihan I Tennekoon
Journal:  Ann Neurol       Date:  2008-11       Impact factor: 10.422

Review 10.  Neurobiology and cellular pathogenesis of glycolipid storage diseases.

Authors:  Steven U Walkley
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2003-05-29       Impact factor: 6.237

View more
  7 in total

1.  Therapeutic approaches for lysosomal storage diseases.

Authors:  Gregory M Pastores
Journal:  Ther Adv Endocrinol Metab       Date:  2010-08       Impact factor: 3.565

Review 2.  Invertebrate models of lysosomal storage disease: what have we learned so far?

Authors:  Samantha Hindle; Sarita Hebbar; Sean T Sweeney
Journal:  Invert Neurosci       Date:  2011-10-25

Review 3.  Lysosomal storage diseases--the horizon expands.

Authors:  Rose-Mary Naaman Boustany
Journal:  Nat Rev Neurol       Date:  2013-08-13       Impact factor: 42.937

4.  Evidence of a progressive motor dysfunction in Mucopolysaccharidosis type I mice.

Authors:  Guilherme Baldo; Fabiana Quoos Mayer; Barbara Martinelli; Anna Dilda; Fabiola Meyer; Katherine P Ponder; Roberto Giugliani; Ursula Matte
Journal:  Behav Brain Res       Date:  2012-05-09       Impact factor: 3.332

Review 5.  Novel Enzyme Replacement Therapies for Neuropathic Mucopolysaccharidoses.

Authors:  Yuji Sato; Torayuki Okuyama
Journal:  Int J Mol Sci       Date:  2020-01-08       Impact factor: 5.923

Review 6.  Factors and processes modulating phenotypes in neuronopathic lysosomal storage diseases.

Authors:  Joanna Jakóbkiewicz-Banecka; Magdalena Gabig-Cimińska; Zyta Banecka-Majkutewicz; Bogdan Banecki; Alicja Węgrzyn; Grzegorz Węgrzyn
Journal:  Metab Brain Dis       Date:  2013-12-05       Impact factor: 3.584

7.  A saposin deficiency model in Drosophila: Lysosomal storage, progressive neurodegeneration and sensory physiological decline.

Authors:  Samantha J Hindle; Sarita Hebbar; Dominik Schwudke; Christopher J H Elliott; Sean T Sweeney
Journal:  Neurobiol Dis       Date:  2016-11-30       Impact factor: 5.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.